Egr2-expressing CD4+LAG3+ regulatory T cells: the therapeutic potential for treating autoimmune diseases
- 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan
- 2Max Planck Center for Integrative Inflammology, The University of Tokyo, Japan
- 3Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Japan
Regulatory T cells (Tregs) are necessary for the maintenance of immune tolerance. Tregs are divided into two major populations: one is thymus-derived and the other develops in the periphery. Among these Tregs, CD4+CD25+ Tregs, which mainly originate in the thymus, have been extensively studied. Transcription factor Foxp3 is well known as a master regulatory gene for the development and function of CD4+CD25+ Tregs. On the other hand, peripherally-developed Tregs consist of distinct cell subsets including Foxp3-dependent extrathymically developed Tregs and IL-10-producing type I regulatory T (Tr1) cells. LAG3 and CD49b are reliable cell surface markers for Tr1 cells. CD4+CD25-LAG3+ Tregs (LAG3+ Tregs) develop in the periphery and produce a large amount of IL-10. LAG3+ Tregs characteristically express the early growth response gene2 (Egr2), a zinc-finger transcription factor, and exhibit its suppressive activity in a Foxp3-independent manner. Although Egr2 was known to be essential for hindbrain development and myelination of the peripheral nervous system, recent studies revealed that Egr2 plays vital roles in the induction of T cell anergy and also the suppressive activities of LAG3+ Tregs. Intriguingly, forced expression of Egr2 converts naïve CD4+ T cells into IL-10-producing Tregs that highly express LAG3. Among the 4 Egr gene family members, Egr3 is thought to compensate for the function of Egr2. Recently, we reported that LAG3+ Tregs suppress humoral immune responses via TGF-β3 production in an Egr2- and Egr3-dependent manner. In this review, we focus on the role of Egr2 in Tregs and also discuss its therapeutic potential for the treatment of autoimmune diseases.
Keywords: Egr2, EGR3, lag3, Foxp3, Regulatory T Cell, Tr1, Gene Therapy, cell therapy
Received: 26 Jun 2017;
Accepted: 06 Feb 2018.
Edited by:Maria Grazia Roncarolo, Stanford University, United States
Reviewed by:Bruce M. Hall, University of New South Wales, Australia
Bin Li, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, China
Maja Wallberg, University of Cambridge, United Kingdom
Copyright: © 2018 Okamura, Yamamoto and Fujio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Keishi Fujio, Graduate School of Medicine, The University of Tokyo, Department of Allergy and Rheumatology, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan, firstname.lastname@example.org